World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   8610 records for 1357 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
AuthorisedYesEUCTR2016-000473-20-HR
A prospective evaluation of natriuretic peptide based referral of chronic heart failure patients in primary care
15/12/2016
RecruitingYesNCT02973529
The Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study
22/11/2016
AuthorisedYesEUCTR2016-000593-38-ES
Efficacy and Safety in a randomised acute pain study of MR308.
25/10/2016
AuthorisedYesEUCTR2016-002207-26-AT
Multicenter Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections
11/10/2016
AuthorisedYesEUCTR2016-002207-26-LV
Multicenter Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections
04/10/2016
RecruitingYesNCT02931838
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
03/10/2016
Not RecruitingYesCTRI/2016/09/007312
LIRA-PRIME: A trial comparing the time period with blood sugar control using Victoza® (liraglutide) vs. oral antidiabetic treatment for up to 104 weeks of treatment in subjects with type 2 diabetes in a primary care setting
27-09-2016
Not RecruitingYesCTRI/2016/09/007304
A clinical investigational study to check effects of GS-5745 (study molecule) in patients with Active Ulcerative Colitis
23-09-2016
Not recruitingNoNCT02913521
Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%
22/09/2016
AuthorisedYesEUCTR2016-001795-30-LV
Evaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2016-001795-30-SKEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.04/10/2016
Not recruitingNCT02964949Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes14/11/2016
AuthorisedEUCTR2016-001795-30-EEEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.03/10/2016
AuthorisedEUCTR2016-001795-30-HUEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.19/10/2016
AuthorisedEUCTR2016-001795-30-ESEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.28/10/2016
AuthorisedEUCTR2016-001795-30-DKEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.19/10/2016
AuthorisedEUCTR2016-001795-30-LTEvaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.04/10/2016
20/09/2016
     
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.3 - Version history